GC Cell announced on the 27th that it has exported self-produced culture media (liquids or solids containing nutrients necessary for cell cultivation) to the Indonesian pharmaceutical company Bifarma (PT Bifarma Adiluhung).
This export of culture media is a follow-up task related to the technology transfer and license agreement signed in September of last year. The company completed the technology transfer in the first half of this year and exported five types of cell culture media to Bifarma for local product production.
Indonesia has about 23,000 new liver cancer patients annually. Among them, approximately 3,000 liver cancer surgical patients are expected to be potential candidates for the immune cell therapy treatment. The company plans to expand the export of immune cell therapy starting with this export to Indonesia.
Meanwhile, Bifarma is a specialized subsidiary of the KALBE Group, the largest pharmaceutical company in Southeast Asia, and has established infrastructure for the production, sales, and logistics of cell therapies locally.